| Literature DB >> 28630687 |
Lamiaa Mohsen1,2, Nermin Ramy1,2, Dalia Saied1,2, Dina Akmal1,2, Niveen Salama1,2, Mona M Abdel Haleim3,2, Hany Aly4.
Abstract
BACKGROUND: Compared to developed countries, the use of antimicrobials in Egypt is less regulated and is available over the counter without the need for prescriptions. The impact of such policy on antimicrobial resistance has not been studied. This study aimed to determine the prevalence of early and late onset sepsis, and the frequency of antimicrobial resistance in a major referral neonatal intensive care unit (NICU).Entities:
Keywords: Antibiotic susceptibility; Blood cultures; Early onset sepsis; Gram positive cocci; Klebsiella pneumoniae; Late onset sepsis; Multidrug resistance; Neonatal sepsis; Tracheal aspirate
Year: 2017 PMID: 28630687 PMCID: PMC5470277 DOI: 10.1186/s13756-017-0225-9
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Demographic characteristics of the study population
| Variable | Early onset sepsis ( | Late onset sepsis ( |
|---|---|---|
| - Gestational age (weeks) | ||
| ≤ 28 weeks (n) (%) | 10 (8.13%) | 12 (6.28%) |
| > 28–32 weeks (n) (%) | 40 (32.52%) | 21 (10.99%) |
| > 32–36 weeks (n) (%) | 32 (26.01%) | 43 (22.51%) |
| > 36 weeks (n) (%) | 41 (33.33%) | 115 (60.20%) |
| - Male/Female (n) | 72/51 | 106/85 |
| - Age on admission (days) (mean ± SD) | 2.41 ± 4.1 | 9.96 ± 9.2 |
| - Length of hospital stay(days) (mean ± SD) | 16.46 ± 16.48 | 18.68 ± 16.61 |
| - Outcome (deaths) (n) (%) | 38 (30.8%) | 32 (16.8%) |
Clinical presentations and diagnoses among studied cases with suspected sepsis
| Clinical manifestation/ diagnosis | Number (%) |
|---|---|
| - Poor suckling & sluggish reflexes | 77 (24.5%) |
| - Respiratory distress | 91 (29.0%) |
| - Pulmonary hypertension | 3 (1.0%) |
| - Meconium aspiration syndrome | 4 (1.3%) |
| - Apnea | 35 (11.2%) |
| - Congenital heart disease | 6 (1.9%) |
| - Neonatal jaundice | 19 (6.1%) |
| - Neonatal convulsions | 12 (3.8%) |
| - Hypoxic ischemic encephalopathy | 11 (3.5%) |
| - Neonatal hypoglycemia | 7 (2.2%) |
| - Multiple congenital anomalies | 10 (3.2%) |
| - Low birth weight | 10 (3.2%) |
| - Neonatal Pneumonia | 15 (4.8%) |
| - Bleeding tendency or hemorrhage | 14 (4.5%) |
| - Total | 314(100%) |
Organisms in blood cultures of infants with early and late onset sepsis (n = 166)
| Blood culture | |||
|---|---|---|---|
| Isolated organism | Early onset sepsis | Late onset sepsis | Total |
| - | 20 | 49 | 69 (41.56%) |
|
| 7 | 14 | 21 (12.65%) |
|
| 3 | 10 | 13 (7.83%) |
|
| 15 | 16 | 31 (18.67%) |
|
| 2 | 7 | 9 (5.42%) |
|
| 0 | 4 | 4 (2.40%) |
|
| 1 | 0 | 1 (0.60%) |
|
| 0 | 3 | 3 (1.80%) |
|
| 0 | 4 | 4 (2.40%) |
|
| 1 | 7 | 8 (4.81%) |
|
| 0 | 1 | 1 (0.60%) |
|
| 0 | 2 | 2 (1.20%) |
| -Total | 166 | ||
CONS coagulase negative staphylococci, MRSA methicillin resistant staphylococcus aureus
Organisms isolated in endotracheal aspirate cultures of infants (n = 79)
| ETA culture | |
|---|---|
| Isolated organism | Total |
| - | 36 (45.6%) |
|
| 23 (29.1%) |
|
| 11 (13.9%) |
|
| 2 (2.5%) |
|
| 4 (5.1%) |
|
| 2 (2.5%) |
|
| 1 (1.3%) |
| Total | 79 |
CONS coagulase negative staphylococci
Resistance of gram negative bacilli to various antimicrobials
| Organism (number) | Ampicillin-sulbactam | Amikacin | Cefotaxime | Ceftazidime | Imipenem | Vancomycin | Ciprofloxacin | Clindamycin | Rifampicin | Piperacillin-tazobactam | |
|
| 105(100%) | 45(43%) | 103(98.1%) | 105(100%) | 22(21%) | ND | 48(45.7%) | ND | ND | 103(98.1%) | |
|
| 44(100%) | 12(27.3%) | 39(88.6%) | 41(93.2%) | 17(38.6%) | ND | 22(50%) | ND | ND | 44(100%) | |
|
| 24(100%) | 8(33.3%) | 20(83.3%) | 21(87.5%) | 9(37.5%) | ND | 8(33.3%) | ND | ND | 24(100%) | |
|
| 1(100%) | 1(100%) | 1(100%) | 1(100%) | 0 | ND | 0 | ND | ND | 1(100%) | |
|
| 6(100%) | 1(16.7%) | 4(66.7%) | 5(83.3%) | 0 | ND | 2(33.3%) | ND | ND | 6(100%) | |
|
| 12(100%) | 3(25%) | 12(100%) | 12(100%) | 2(16.7%) | ND | 5(41.7%) | ND | ND | 12(100%) | |
|
| 2(100%) | 0 | 2(100%) | 2(100%) | 1(50%) | ND | 2(100%) | ND | ND | 2(100%) | |
| Gentamicin | Meropenem | Cefoperazone | Cefepime | Amoxicillin-clavulanate | Ceftriaxone | Cotrimoxazole | Erythromycin | Cefoxitin | Levofloxacin | Cefuroxime | |
|
| 63(60%) | 34(32.4%) | 103(98.1%) | 86(81.9%) | 101(96.2%) | 103(98.1%) | 86(81.9%) | ND | 82(78.1%) | 25(24%) | 105(100%) |
|
| 21(47.7%) | 20(45.5%) | 39(88.6%) | 28(63.6%) | 43(97.7%) | 44(100%) | 37(84.1%) | ND | 38(86.4%) | 8(18%) | 44(100%) |
|
| 7(29.2%) | 10(41.7%) | 21(87.5%) | 14(58.3%) | 24(100%) | 24(100%) | 19(79.2%) | ND | 16(66.7%) | 7(29%) | 24(100%) |
|
| 1(100%) | 0 | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 0 | ND | 1(100%) | 0 | 1(100%) |
|
| 1(16.7%) | 0 | 6(100%) | 5(83.3%) | 6(100%) | 6(100%) | 2(33.3%) | ND | 2(33.3%) | 1(17%) | 6(100%) |
|
| 8(66.7%) | 4(33.3%) | 12(100%) | 8(66.7%) | 11(91.7%) | 12(100%) | 10(83.3%) | ND | 11(91.7%) | 3(25%) | 12(100%) |
|
| 0 | 1(50%) | 2(100%) | 2(100%) | 2(100%) | 2(100%) | 2(100%) | ND | 1(50%) | 2(100%) | 2(100%) |
ND Sensitivity was not done, E coli Escherichia coli, Klebsiella Klebsiella pneumoniae, Pseudomonas Pseudomonaas aeruginosa
Resistance of gram positive cocci to various antimicrobials
| Organism (number) | Ampicillin-sulbactam | Amikacin | Cefotaxime | Ceftazidime | Imipenem | Vancomycin | Ciprofloxacin | Clindamycin | Polymyxin | Rifampicin | Piperacillin-tazobactam |
|
| 33(100%) | 16(48.5%) | 31(93.9%) | 31(93.9%) | 28(84.8%) | 8(24.2%) | 25(75.8%) | 18(55%) | ND | 15(46%) | 33(100%) |
|
| 9(100%) | 3(33.3%) | 9(100%) | 9(100%) | 8(88.9%) | 0 | 8(88.9%) | 3(33%) | ND | 3(33%) | 9(100%) |
|
| 4(100%) | 2(50%) | 3(75%) | 3(75%) | 2(50%) | 1(25%) | 3(75%) | 3(75%) | ND | 4(100%) | 4(100%) |
|
| 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 0 | 0 | 1(100%) | ND | 1(100%) | 1(100%) |
|
| 4(100%) | 3(75%) | 4(100%) | 4(100%) | 4(100%) | 0 | 3(75%) | 2(50%) | ND | 2(50%) | 4(100%) |
| Gentamicin | Meropenem | Cefoperazone | Cefepime | Amoxicillin-clavulanate | Ceftriaxone | Cotrimoxazole | Erythromycin | Cefoxitin | Levofloxacin | Cefuroxime | |
|
| 18(55%) | 28(85%) | 33(100%) | 29(88%) | 26(79%) | 33(100%) | 27(82%) | 28(85%) | 25(76%) | 22(67%) | 33(100%) |
|
| 7(77.8%) | 9(100%) | 9(100%) | 9(100%) | 9(100%) | 9(100%) | 8(89%) | 7(78%) | 9(100%) | 7(78%) | 9(100%) |
|
| 0 | 2(50%) | 4(100%) | 2(50%) | 3(75%) | 4(100%) | 4(100%) | 4(100%) | 3(75%) | 4(100%) | 4(100%) |
|
| 0 | 1(100%) | 1(100%) | 0 | 0 | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) |
|
| 4(100%) | 4(100%) | 4(100%) | 4(100%) | 0 | 4(100%) | 4(100%) | 4(100%) | 3(75%) | 4(100%) | 4(100%) |
ND sensitivity was not done, CONS coagulase negative staphylococci, MRSA methicillin resistant staphylococcus aureus, St streptococcus, Staph. aureus Staphylococcus aureus